Anand S. Srivastava, MS, Ph.D.

15 Pages·2014·0.33 MB·English

4370 La Jolla Village Drive, 4th Floor, San Diego, California 92122, USA www.GIOSTAR.com

Anand S. Srivastava, M.S., Ph.D.
Chairman & Cofounder
[email protected]

Dr. Anand Srivastava has been associated with leading universities and research institutions of
USA. In affiliation with University of California San Diego Medical College (UCSD), University
of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute
For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA),
USA has developed several research collaborations and has an extensive research experience in the
field of Stem cell which is documented by several publications in revered scientific journals.

Dr. Srivastava is a Chairman and Cofounder of California based Global Institute of Stem Cell
Therapy and Research (GIOSTAR) headquartered in San Diego, California, (U.S.A.). The
company was formed with the vision to provide stem cell based therapy to aid those suffering from
degenerative or genetic diseases around the world such as Parkinson's, Alzheimer's, Autism,
Diabetes, Heart Disease, Stroke, Spinal Cord Injuries, Paralysis, Blood Related Diseases, Cancer
and Burns. GIOSTAR is a leader in developing most advance stem cell based technology, supported
by leading scientists with the pioneering publications in the area of stem cell biology. Company’s
primary focus is to discover and develop a cure for human diseases with the state of the art unique
stem cell based therapies and products. The Regenerative Medicine provides promise for treatments
of diseases previously regarded as incurable.

Giostar is world’s leading Stem cell research company involved with stem cell research work for
over a decade. It is headed by Dr Anand Srivastava, who is a world-renowned authority in the field
of Stem cell biology, Cancer and Gene therapy. Several governments and organizations including
USA, India, China, Turkey, Kuwait, Thailand, Philippines, Bahamas and many others seek his
advice and guidance on drafting their strategic & national policy formulations and program
directions in the area of stem cell research, development and its regulations. Under his creative
leadership a group of esteemed scientists and clinicians have developed and established Stem cell
therapy for various types of Autoimmune diseases and blood disorders.

Dr. Srivastava is working as a director of Stem cell program and developing the stem cell policies
and programs for following governments and organization:
1. Directed stem cell core facility for Salk Research Institute, San Diego, USA
2. Organized stem cell program for University of California, Los Angeles, USA
3. Advised Japanese Research Institute for developing genomic program, Japan
4. Guided scientists in developing stem cell program for Turkey, Kuwait and Saudi Arabia
5. Stem cell program Director for State of Gujarat, India
6. Stem cell program Director for State of Madhya Pradesh, India
7. Stem cell program Director for State of Chattishgarh, India
8. Stem cell program Director for University of Baroda, Gujarat, India
9. Stem Cell program advisor for Asian Medical School, Kyrgyzstan

1 of 15
Global Institute of Stem Cell Therapy and Research
Office: 4370 La Jolla Village Drive, 4th Floor, San Diego, California 92122, U.S.A.---- Mail: P.O. Box 270575, San Diego, California 92198, U.S.A.
www.giostar.com --- [email protected]
Giostar is the only official collaborator of Government of Gujarat, Government of Madhya Pradesh
and Government of Chattishgarh, India by setting up a state of art stem cell treatment hospital for
the less fortunate tribal populace of India suffering from Sickle Cell Anemia. Several more state
Governments in India is looking for collaborative efforts of GIOSTAR and Dr. Srivastava to
develop stem cell transplant program in their respective states.

SUMMARY OF DR. SRIVASTAVA’S WORK:

Dr. Anand Srivastava’s success has its root in his unique background of expertise in Stem cell
biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem
cell, tissue targeting, gene therapy and clinical research. There are many scientists who can work in
a narrowly defined field but few have broad and multidisciplinary experience to carry out clinical
research in a field as challenging as Stem cell biology, cancer and gene therapy field. Dr. Anand
Srivastava’s wide-spectrum expertise is rare in clinical research and perfectly crafted to fit ideally
with the GIOSTAR projects for Stem cell transplant, cancer and gene therapy research.

Dr. Anand Srivastava’s research work has been presented in various national and international
scientific meetings and conferences in India, Japan, Germany and USA. His research articles have
been published in peer reviewed medical scientific journals and he has been cited extensively by
other scientists. Dr. Anand Srivastava’s expertise and scientific achievements were recognized by
many scientific fellowships and by two consecutive award of highly prestigious and internationally
recognized, JISTEC award from Science and Technology Agency, Government of Japan. Also, his
research presentation was awarded with the excellent presentation award in the “Meeting of Clinical
Chemistry and Medicine, Kyoto, Japan. He has also expertise in genetic engineering research,
developmental biology, immunology, making the transgenic animals and his extraordinary expertise
of searching and characterizing the new genes are ideal for our ongoing projects of developing the
effective treatments for many degenerative diseases, genetic diseases and cancer. Based on his
extraordinary scientific achievements his biography has been included in “WHO IS WHO IN
AMERICA” data bank two times, first in 2005 and second in 2010.

POSITIONS HELD BY DR. SRIVASTAVA (1997 to Date):

1. Chairman & Cofounder (2008-till date): Global Institute of Stem Cell Therapy and
Research, San Diego, CA. USA.
2. Associate Professor: Department of Cellular and Molecular Biology, School of Medicine,
University of California Los Angeles (UCLA), CA, USA.
3. Visiting Senior Scientist: Department of Stem Cell Biology, Burnham Research Institute
for Medical Science, San Diego, CA, USA.
4. Senior Scientist: Stem Cell Core Facility, The Salk Research Institute, La Jolla, CA, USA.
5. Associate Professor: Department of Stem Cells and Neurology, School of Medicine,
University of California Irvine (UCI), Irvine, CA, USA.
6. Assistant Professor: Cancer Center, School of Medicine, University of California San
Diego (UCSD), La Jolla, CA, USA
7. Honorary Visiting Professor: National Research Institute, Nansei, Mie, JAPAN.

SPECIAL STEM ISSUES OF JOURNALS DEVOTED TO DR. SRIVASTAVA

1. Current Topics of Medicinal Chemistry among top five medicinal chemistry journal
devoted its special issue of stem cell to Dr. Srivastava in 2010.
2. Stem Cell International devoted its special issue on stem cells to Dr. Srivastava in 2012.
2 of 15
Global Institute of Stem Cell Therapy and Research
Office: 4370 La Jolla Village Drive, 4th Floor, San Diego, California 92122, U.S.A.---- Mail: P.O. Box 270575, San Diego, California 92198, U.S.A.
www.giostar.com --- [email protected]
3. Potentials of ES cell therapy in neurodegenerative diseases (Curr Pharm Des;
2008;14:3873-9) by Dr. Srivastava is still holding number one position among top 20
articles published since 2008 in the field rated by BIoMedLib in 2012.

EXPERT SCIENTIFIC REVIEWER FOR LEADING JOURNALS OF MEDICINE:

Dr. Srivastava is the member of the several scientific review committees and reviewing the research
grants. He has written several review articles and scientific manuscripts. He is also the reviewer and
editor of several scientific journals.
1. Advances in Stem Cells
2. Current pharmaceutical Design
3. Current Topics in Medicinal Chemistry
4. Stem Cells
5. Stem Cell International
6. Current in Cell Medicine
7. Journal of Stem Cell Research and Therapy
8. Conference Papers in Molecular Biology
9. Journal of Pharmaceutics
10. Current Pharmaceutical Biotechnology
11. Open Journal of Organ Transplant Surgery
12. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry
13. Stem Cells and Cloning: Advances and Applications
14. Blood and Lymphatic Cancer: Targets and Therapy
15. Degenerative Neurological and Neuromuscular Disease
16. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
17. Immuno Targets and Therapy
18. Current Vascular Pharmacology
19. Gastrointestinal Cancer: Targets and Therapy
20. Journal of Bioengineering and Biomedical Sciences
21. The Application of Clinical Genetics
22. Journal of Tissue Science & Engineering
23. Neuropsychiatric Disease and Treatment
24. Current Tissue Engineering
25. Hepatic Medicine: Evidence and Research
26. Current Drug Discovery Technologies
27. Current Bioactive Compounds
28. Transplant Research and Risk Management
29. Biosimilars
30. Current Drug Delivery
31. Journal of Experimental Pharmacology
32. Open Journal of Regenerative Medicine
33. Current Diabetes Reviews
34. Journal of Fertilization: In Vitro
35. Clinical and Translational Medicine

FELLOWSHIPS/ AWARDS:

2003 Awarded with “NIMA (National Integrated Medical Association) Outstanding
Scientist” award from NIMA, India.
2003 Awarded with “Excellent Scientist Award” from Bharat Vikas Parisad, India for
continuous excellent performance in the life science research.
3 of 15
Global Institute of Stem Cell Therapy and Research
Office: 4370 La Jolla Village Drive, 4th Floor, San Diego, California 92122, U.S.A.---- Mail: P.O. Box 270575, San Diego, California 92198, U.S.A.
www.giostar.com --- [email protected]
The 18th International Congress of Clinical Chemistry and Laboratory Medicine Kyoto
“Excellent Poster Award”, Kyoto, Japan.
2002 “Best Scientist Award” for excellent contribution in the field of life science research
from Kayastha Maha Sabha, Varanasi, India.
1998-2000: “Long-term STA/JISTEC Award” (Science and Technology Agency/Japan
International Science and Technology Exchange Center, JAPAN)- Fellowship award
for two year from government of Japan.
1997-1998: “Short-term STA/JISTEC Award” (Science and Technology Agency/Japan
International Science and Technology Exchange Center, JAPAN)- Fellowship Award
for three months from government of Japan (October 1997- January 1998).
1997-1998: Awarded with “Research Associate-ship award” from CSIR (Council of Scientific
and Industrial Research) Government of India.
1990-1995: “CAS (Center of Advanced Study) Award” in Zoology. A doctoral research
fellowship award from Government of India.

THE FOLLOWING SUMMARIZES DR. SRIVASTAVA’S MAJOR SCIENTIFIC
ACHIEVEMENTS:

1. Dr. Srivastava developed the animal material free and serum free Human embryonic Stem
cell culture condition to use the Human ES cells to treat the human diseases.
2. Dr. Srivastava for the first time showed that if the ES cell injected into developing fetuses in
utero takes participation in development of all body of a living organism.
3. For the first time he showed that ES cell is better accepted by the transplanted animals in
comparison to adult stem cells.
4. For the first time he showed the way to generate the high number of pre-erythrocytes using
glucocorticoid hormone. Which may be use to treat several blood diseases.
5. For the first time Using ES cells he generated the high number of CD34+ expressing a kind
of hematopoietic stem cell which can be used to treat several autoimmune diseases, immune
reconstitution and blood diseases.
6. For the first time he showed the molecular mechanism behind the regulation of ES cell
differentiation into hematopoietic cells.
7. For the first time he showed that ES cells automatically recognize the damage portion of the
brain and can be used to repair the damage brain.
8. For the first time he showed that ES cell can be used to treat the Crohn’s disease a kind of
colon cancer.
9. For the first time, he demonstrated that the mammalian fetuses can be programmed inside
the mother uterus to face the challenges of the future possible infection. This finding is very
important to develop the advanced therapy for any fatal disease such as cancer and AIDS.
Utilizing these techniques, fetuses can be given information about all possible infections and
the capability to counter those infections and disease.
10. He has demonstrated for the first time that it is easy to correct the genetic diseases in
developing fetus in utero in comparison to adult animals.
11. He has shown for the first time that the lung cancer cells can be treated with the help of
plant product curcumin and can be used as effective cancer therapeutic agent. He also
demonstrated that how curcumin regulated the genes related to programmed death of
cancerous cell. Finding help in development of non-toxic, less expensive, easily available
drug for cancer.
12. The biggest problem in the treatment of cancer and other diseases is the non-specific
distribution of medicine and toxic chemotherapeutic agents to healthy tissues. Dr. Srivastava
for the first time developed a technique that can help in targeting the diseased tissues using
the tissue receptor binding peptide ligands. These techniques can be used for targeted
4 of 15
Global Institute of Stem Cell Therapy and Research
Office: 4370 La Jolla Village Drive, 4th Floor, San Diego, California 92122, U.S.A.---- Mail: P.O. Box 270575, San Diego, California 92198, U.S.A.
www.giostar.com --- [email protected]
delivery of drugs and genes (in case of genetic disease) to the specific fetal tissues inside the
mother uterus without harming the normal tissues of mother and fetus.
13. For the first time, He demonstrated the insertion of foreign pancreas enzyme specific gene
promoter into the developing animals embryo and successfully shown the incorporation and
regulation of pancreatic enzyme in the control of inserted gene. This is very important
finding and proves that the defective genes can be replaced easily and effectively by the
normal functional genes during the development of animals. This finding will help in the
change of defective genes of insulin hormone, which is present in the pancreas of diabetic
patients and many other genetic diseases also.
14. For the first time, He reported the gene sequence of all important pancreatic enzymes (three
isoform of trypsinogen, two isoforms of chymotrypsinogen, four types of elastases, three
forms of carboxypeptidases and lipase) and its evolutionary relationship with human. Also,
he reported first time the regulation of digestion by these enzymes in the alimentary canal
during digestion of proteins in the developing animals.
15. For the first time, He cloned and sequenced two types of human homologue of Vitamin D
receptor gene from Japanese flounder, which is most important receptor, which help in the
development of bone. Before my report, characters of this gene were not known in Japanese
flounder. This finding helped in the understanding of the genetic evolution of mammals.
16. For the first time, he cloned and sequenced the homologue of human placental protein,
PP11, and mouse T cell specific, Tcl-30, in pancreas of Japanese flounder, this study
suggest that these genes evolved from the fish pancreas and in fish it helps in synthesizing
the digestive enzymes but during the evolution its function got changed and work differently
in the mammalian placenta. This was very important finding related to this rare gene.
17. For the first time, He has shown that the Hox and sonic hedgehog genes regulate the
development of bones and respiratory organs. He also demonstrated that how these genes
could be regulated artificially. This was very important finding because it gives the idea that
how genes regulate the development of organs.
18. For the first time, He has purified and characterized the human homolog of AAT and ASPT
enzymes, which is the basic clinical marker in all the infection and major marker of liver
function test.
19. For the first time, he demonstrated the co-ordination of AAT and ASPT enzymes in the
production of energy through the amino acids after aerobic respiration.
20. For the first time, he has shown that according to metabolic demand of the body AAT and
ASPT genes synthesized additional forms of its isoform to cope up with the extra energy
demand and work as an “on” and off” switch.

DR. SRIVASTAVA’S EXCELLENCE IN SEVERAL ADVANCED BIOLOGICAL
TECHNIQUES:

Techniques related to Human Embryonic Stem Cell
Human Embryonic Stem cell culture, Serum free and feeder free hES cell culture, in vitro
differentiation of hES cells into neural cells, in vitro differentiation of hES into hematopoietic cells
and red blood cells under the control of cytokines. Gene regulation studies using RT-PCR, Real
time PCR, Northern blot, Southern blot and in situ hybridization, immunohistochemistry during the
differentiation, Cell cycle regulation studies during differentiation of hES cells into hematopoietic
and neural cells. Use of siRNA for blocking a specific cell cycle. FACS analysis of differentiated
cells and cell shorting. ES cell transfection.

In vivo studies with ES cells
Created a mouse model for study the effect of ES cells on damaged brain. Injection of ES cells into
mouse brain, tail vein injection, in vivo tracking of ES cell migration. Used the ES cells for repair of
damaged brain. Gene and protein regulation during neural cell differentiation. Studies on
5 of 15
Global Institute of Stem Cell Therapy and Research
Office: 4370 La Jolla Village Drive, 4th Floor, San Diego, California 92122, U.S.A.---- Mail: P.O. Box 270575, San Diego, California 92198, U.S.A.
www.giostar.com --- [email protected]
transcription factors. Histochemical analysis of transplanted ES cells using fluorescent, confocal
microscopy and deconvolution microscopy.
Created a mouse model for Crohn’s disease. In vivo migration of ES cells into diseased portion of
intestine. Studies on inflammatory cytokines during the repair of Crohn’s disease with ES cell.
Gene regulation studies during this process. Elisa assays for the cytokines. Stem cell niche
interaction.

Created in utero mouse model for ES cells transplantation. Used this model to make chimeric
animals. Distribution and differentiation of ES cells into developing mouse embryo. FACS and
magnetic shorting of ES cells derived CD31+, CD34+, CD45+ cells from the transplanted animal
tissues. Gene and protein regulation of in vivo differentiating cells.

Created immunocompromised mouse model to study the effect of in vivo immune component on T7
phage virus. In vivo selection of tissue specific receptor binding peptide using in vivo biopanning
method. Tissue targeted gene delivery to correct the blood related genetic diseases. Gene cloning,
gene sequencing, synthesis of RNA probes.
Protein and enzyme biochemistry
Protein assay, peptide structure and amino acid sequencing, Enzyme assay, Ultra centrifugation, Ion
exchange chromatography, column chromatography, HPLC, Protein and gene regulation during the
development. Enzyme kinetics, Enzyme inhibition, SDS gel electrophoresis, Protein
characterization.

Selection of cell receptor binding peptide and Phage display technology
- Selection of tissue receptor binding peptides using T7 phage display system.
- In vivo and in vitro biopanning for selection of receptor binding peptides sequences.
- Characterization of targeted cells and tissues using histochemistry and gene expression analyses.
- In vivo delivery of drugs and genes to targeted tissues using microinjection.

Cancer Research
- Studying the role of pharmaceutical agent curcumin as an anti-lung cancer drug and develop it
as a non-toxic cancer drug.
- Role of apoptotic genes on the lung cancer cell lines.
- Development of tissue targeted delivery protocol of pharmaceuticals agents for cancer and
genetic diseases.

Fluorescence techniques for nucleic acid sequence detection: Clinical and diagnostic
applications
- Fluorescent labeling of DNA and RNA probes.
- Fluorescence resonance energy transfer (FRET) protocols for DNA and RNA sequence.
detection in real time (Sequence Detection System 7700, ABI, Perkin Elmer)
- FRET protocols for monitoring ribozyme reactions and kinetics in real time (TaqMan, SDS
7700, ABI, Perkin Elmer).
- Accessibility studies for DNA and RNA target sequences using FRET.
- Fluorescence polarization protocols for monitoring ribozyme reactions (POLARstar, BMG,
GmbH) and for DNA and RNA sequence detection.
- Sequence detection with Syber green dye in real time quantitative PCR by Light Cycler (Roche
Diagnostics, USA).
- Single nucleotide polymorphism detection in real time with LightCycler hybridization probes
(Roche Diagnostics, USA).

Gene detection technology: Research and Clinical applications
- Preparation of radio labeled & fluorescent labeled RNAs (ribozymes and target substrates).
6 of 15
Global Institute of Stem Cell Therapy and Research
Office: 4370 La Jolla Village Drive, 4th Floor, San Diego, California 92122, U.S.A.---- Mail: P.O. Box 270575, San Diego, California 92198, U.S.A.
www.giostar.com --- [email protected]
- In vitro transcription of RNA.
- Expression of ribozymes in yeast.
- Isolation and purification of cellular RNA.
- RNase Protection Assay.
- Kinetic characterization of ribozymes & binding kinetics using fluorescence methods.
- Designing, synthesis and characterization of allosteric ribozymes induced by small drug ligands
(such as theophylline & caffeine).

- Developed in utero microinjection techniques to transplant the bone marrow and stem cells to
cure blood related genetic disease.
- Harvest the fetal liver, bone marrow and mouse embryonic stem cells for transplantation.
- Culture mouse embryonic stem cell and in vitro differentiation into the blood cells.
- Fractionation of cells using flow cytometry techniques.

Standard Molecular biology techniques
- Standard and site directed mutagenesis polymerase chain reaction (PCR).
- Preparation and purification of plasmids.
- Transformations and Transfection of DNA.
- Cloning of DNA.
- Solid phase synthesis of DNA (Gene Assembler, Pharmacia).
- DNA sequencing & fragment analyses (ABI 310 Gene Sequencer, Perkin Elmer).
- Quantitation of DNA, RNA and proteins.
- Mammalian cell culture and yeast culture.
- Gel electrophoresis (polyacrylamide and agarose).
- Capillary gel electrophoresis (ABI 310 Gene Sequencer, Perkin Elmer).
- Column/ gel/ thin layer chromatography.
- Autoradiography by phosphorimager (Storm, Molecular Dynamics, USA).
- High Performance Liquid Chromatography (HPLC).
- Preparation and purification of chemical reagents & solvents.
- Enzyme/ Protein/ purification and characterization.
- Isolation of Genomic DNA, Genomic library Construction.
- Radioimmunoassay.

General molecular and biochemical techniques
mRNA preparation and purification, Primer designing, Real-time PCR, RT-PCR, DNA cloning,
DNA sequencing, Isolation of Genomic DNA, Genomic library Construction, Transformation,
Transfection, Cell culture, Plasmid purification, RNA probe making, Different kinds of microscopy,
In situ hybridization, Southern blotting, Northern blotting, Western blotting, Spectrophotometery,
In utero-microinjection, Column chromatography, HPLC, PAGE, Agarose gel-electrophoresis,
Enzyme assay, Protein assay, Enzyme/ Protein/ DNA purification, Histology, Phage display for
tissue targeting, Radio-immunoassay.

7 of 15
Global Institute of Stem Cell Therapy and Research
Office: 4370 La Jolla Village Drive, 4th Floor, San Diego, California 92122, U.S.A.---- Mail: P.O. Box 270575, San Diego, California 92198, U.S.A.
www.giostar.com --- [email protected]
INVITED SPEAKER AND PRESENTATIONS OF DR. SRIVASTAVA’S SCIENTIFIC
FINDINGS IN NATIONAL AND INTERNATIONAL CONFERENCES:

1. Srivastava A.S. Invited Speaker, STEM 2013, 9Th Annual Conference on Biotechnology -
Focusing On Latest Trend in Stem Cells, Regenerative Medicine and Tissue Engineering Mumbai,
India, January 2013.

2. Srivastava A.S. "International Conference on Regenerative and Functional Medicine"
(Regenerative Medicine-2012), San Antonio, USA. November 2012.

3. Sriavstava A.S. 2nd International Congress on Neurology & Epidemiology; "Impact of drugs on
the natural history of neurological diseases". Nice, France. November 2012.

4.
 Srivastava
 A.S.
 Invited
 Speaker,
 International
 Expo
 and
 Conference
 on
 Analytrix
 &
 HPLC,

Chicago,
 USA.
 October
 2012.

5. Srivastava A.S. Invited Speaker at "International Conference on Emerging Cell Therapies" (Cell
Therapy-2012) Chicago, USA. October 2012.

6. Srivastava A.S. Invited Speaker, 6th Neurodegenerative Conditions Research and Development
Conference San Francisco, CA, USA. September 2012.

7. Srivastava A.S. 8th International Congress on Mental Dysfunction & Other Non-Motor Features
In Parkinson's Disease and Related Disorders, Berlin, Germany. May 2012.

8. Srivastava A.S. International Conference and Exhibition on Neurology & Therapeutics Las
Vegas, USA. May 2012.

9. Srivastava A.S. Montreal International Biotechnology Forum, Montreal, Quebec, Canada.
May 2012.

10. Srivastava A.S. Invited Speaker, International Association of Neurorestoratology (IANR) V
and 9th Global College Neuroprotection and Neuroregeneration (GCNN) conference with the 4th
International Spinal Cord Injury Treatment & Trial Symposium (ISCITT) Xi’an City, China. May
2012.

11. Srivastava A.S. International Forum on the Mediterranean Diet, Ravello - Amalfi Coast, Italy.
March 2012

12. Srivastava A.S. Hong Kong international Stem Cell Forum 2012, Hong Kong. February 2012.

13. Srivastava A.S. 4th International Conference on Drug Discovery and Therapy" (4th ICDDT
2012) Dubai, UAE, February 2012.

14. Srivastava A.S. Evolving Strategies in Hematopoietic Stem Cell Transplantation- San Diego,
USA. February 2012.

15. Srivastava A.S. Hebei International Biotechnology Forum; Shijiazhuang, Hebei, China.
November 2011

8 of 15
Global Institute of Stem Cell Therapy and Research
Office: 4370 La Jolla Village Drive, 4th Floor, San Diego, California 92122, U.S.A.---- Mail: P.O. Box 270575, San Diego, California 92198, U.S.A.
www.giostar.com --- [email protected]
16. Srivastava A.S. 3rd International Conference on Drug Discovery and Therapy. Regenerative
Medicine. Dubai, UAE. February 2011.

17. Srivastava A.S. 3rd Annual Congress of Regenerative Medicine & Stem Cell-2010,
Shanghai, China. December 2010.
18. Srivastava A.S. 1st Annual Tetra-Congress of MolMed-Personal Medicine Congress 2010,
Shanghai, China. November 2010.
19. Srivastava A.S. International Association of Neurorestoratology(IANR), American Journal of
Neuroprotection and Neuroregeneration, Beijing, China. October 2010.
20. Srivastava A.S. EPS Global International Neuroscience Forum. Nha Trang, Vietnam.
October 2010.
21. Srivastava A.S. EPS Global International Neuroscience Forum, Guangzhou, China.
September 2010.
22. Srivastava A.S. 4th Academic Congress of International Chinese Neurosurgical Sciences.
Chengdu, China. June 2010.
23. Srivastava A.S. 1st Annual World Congress of Immunodiseases and Therapy (WCIT 2010).
Beijing, China. May 2010.
24. Srivastava A.S. 3rd PepCon-2010 - Protein Misfolding and Neurodegeneration. Beijing,
China. March 2010
25. Srivastava A.S. Potential use of ES cells in hematopoietic and neural diseases. City of Hope
National Medical Center, Duarte, California, USA. January, 2009.

26. Srivastava A.S. Differentiation of Human Embryonic Stem cell into erythrocyte and neural
precursor cells: Its potential application. Cleveland Clinic, Cleveland, Ohio, USA, December,
2008.

27. Srivastava A.S. Potential of ES cell in repair of Hematopoietic and neural diseases.
International Conference in Stem cell, Kerala, India, August, 2008.

28. Srivastava A. S., Singh U. and Carrier E. Embryonic stem cell improve colitis and decrease IL-
12 levels in the colitis mice. BMRP Fourth Annual Investigator Meeting, Los Angeles, USA.
2006

29. Carrier E., Shermila Kausal and Srivastava A. S. Gene Regulation During the Erythrocytic
Differentiation of Embryonic Stem Cells. Blood (ASH Meeting), 2005.

30. Carrier E., Shermila Kausal and Srivastava A. S. Differentiation of Human ES cell into the
Hemangioblast. Blood (AHS Meeting), 2005.

31. Srivastava A.S., Zhongling F., Victor A., Kim H.S. and Carrier E. Repair of Crohn’s disease
with embryonic stem cells. Broad Medical Research Program, Third Annual Investigator
Meeting, Los Angeles, CA, USA, 2005.

32. Srivastava A.S., Shenouda S. and Carrier E. Damaged murine brain induces ES cells into
migration and proliferation. Blood:104, 779a, 2004.
9 of 15
Global Institute of Stem Cell Therapy and Research
Office: 4370 La Jolla Village Drive, 4th Floor, San Diego, California 92122, U.S.A.---- Mail: P.O. Box 270575, San Diego, California 92198, U.S.A.
www.giostar.com --- [email protected]
33. Srivastava A.S., Shenouda S. and Carrier E. Increased expression of OCT4,SOX2 and FGF4
genes following injection of embryonic stem cell into damaged murine brain. American Society of
Gene Therapy, 2004.

34. Srivastava A.S. and Carrier E.; Distribution and stability of T7 phage in mouse blood and
tissues. Molecular Therapy:7, 230, 2003.

35. Moustafa M., Srivastava A.S., Nedelcu E., Minev B., Carrier E.; Chimerism and tolerance post
in utero transplantation with ontogenically different sources of stem cells. 32nd annual meeting of
the international society for Experimental Hematology, 31, 274, 2003 (Paris, France).

36. Steve S., Srivastava A.S. Carrier E.; In vivo survival of hematopoietic stem cell in mouse
brain.11th international symposium on recent advances in Stem cell transplantation, 89-90, 2003
(San Diego, USA).

37. Srivastava A.S., Carrier E.; Distribution and stability of T7 phage in mouse. 11th international
symposium on recent advances in Stem cell transplantation, 93, 2003 (San Diego, USA).

38. Elena N., Srivastava A.S., Varki N.M., Assatourian G. and E. Carrier; Embryonic stem cells
survive and proliferate after intraperitoneal In utero transplantation and produce teratocarcinomas.
Blood:160b, 2002.

39. Srivastava A.S and E. Carrier; In utero targeting the fetal liver by using T7 phage display
system. Blood:489b, 2002.

40. Srivastava A.S. and E. Carrier; Factor responsible for in vivo neutralization of T7 phage
display vector in the blood of mice. Blood:489b, 2002.

41. Srivastava A.S. and E. Carrier; Distribution and stability of T7 phage in the mouse after
intravenous administration. ICCC, Kyoto, Japan. (October 2002).

42. Srivastava A.S., T. Kaido and E. Carrier; Immunological factors that affect the in vivo fate of
T7 phage in the mouse. Molecular Therapy:5, 713, 2002.

43. Srivastava A.S., E. Nedelcu and E. Carrier; Engraftment of murine embryonic stem cells after
in utero transplantation. Molecular Therapy:5, 1132, 2003.

44. M. Rizzi, T. Kaido, M.Gerloni, K.Schuler, A. S. Srivastava, E.Carrier and M. Zanetti; Neonatal
T cell immunity by in utero immunization. AAI 2002 annual meeting, April 20 - 24, New
Orleans, Experimental Biology 2002 sponsored by 7 FASEB societies.

45. Srivastava A.S., T. Kaido and E. Carrier; Kinetics of T7 phage neutralization in the blood of
normal and immunodeficient mice. Blood:407, 2001.

46. Hassan S., Jody D., Srivastava A.S., T.H. Lee, M.P. Busch, Carrier E.; Immunity without
microchimerism after in utero transplantation of Hematopoietic stem cell. Blood:320, 2001.

47. Srivastava A.S., Felix Tinkov, T. Friedmann and E. Carrier; Detection of T7 phage in the fetus
after Systemic administration to pregnant mice. Molecular Therapy:4, 760, 2001.

10 of 15
Global Institute of Stem Cell Therapy and Research
Office: 4370 La Jolla Village Drive, 4th Floor, San Diego, California 92122, U.S.A.---- Mail: P.O. Box 270575, San Diego, California 92198, U.S.A.
www.giostar.com --- [email protected]